Connect your AI

CorMedix CRMD Unrealized Gain (Loss), Foreign Currency Transaction, before Tax

Unrealized Gain (Loss), Foreign Currency Transaction, before Tax at other companies

Mirum Pharmaceuticals, Inc.MIRM

-$1.1M-267%

Medline, Inc. MDLN

——

Other financials

Income statement

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossUnrealized.

The official record: CorMedix’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's unrealized gain (loss), foreign currency transaction, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CorMedix's unrealized gain (loss), foreign currency transaction, before tax?: CorMedix (CRMD) reported unrealized gain (loss), foreign currency transaction, before tax of $21.5K in Q4 2025.
What does unrealized gain (loss), foreign currency transaction, before tax mean?: Measures the non-cash impact of exchange rate changes on monetary assets and liabilities denominated in currencies other than the company's functional currency. It reflects unrealized gains or losses that have not yet been settled through actual cash transactions. This metric provides insight into the company's sensitivity to global currency market fluctuations.